Dasatinib for the Treatment of Moderate and Severe COVID-19

NCT04830735 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped PI decided not to pursue study

Conditions

Symptomatic COVID-19 Infection Laboratory-Confirmed

Interventions

DRUG: Dasatinib Anhydrous
DRUG: Placebo Administration

Sponsor

University of Southern California

Collaborators

[object Object]